SILVERARC CAPITAL MANAGEMENT LLC's Q2 2024 13F: 12 new positions, 19 exits
Form 13F-HR for the quarter ended Jun 30, 2024 · filed Aug 14, 2024 · 66 reported positions · accession 0001420506-24-001528
What changed this quarter
| Activity | Security | Weight before | Weight now | Change | Shares | Shares % |
|---|---|---|---|---|---|---|
| Increased | NUVALENT INC (NUVL) | 3.3% | 8.7% | +5.4 pts | +308K sh | +195% |
| Increased | ERASCA INC (ERAS) | 0.1% | 4.6% | +4.4 pts | +7.59M sh | +3392% |
| Increased | INTRA-CELLULAR THERAPIES INC (ITCI) | 0.7% | 3.3% | +2.6 pts | +158K sh | +453% |
| Increased | UROGEN PHARMA LTD (URGN) | 2.1% | 4.6% | +2.4 pts | +593K sh | +117% |
| Exited | ALPINE IMMUNE SCIENCES INC (ALPN) | 2.2% | — | −2.2 pts | −199K sh | −100% |
| New | ALNYLAM PHARMACEUTICALS INC (ALNY) | — | 2.2% | +2.2 pts | +36,000 sh | new |
| New | SYNDAX PHARMACEUTICALS INC (SNDX) | — | 1.9% | +1.9 pts | +370K sh | new |
| Increased | ELUTIA INC (ELUT) | 0.1% | 2.0% | +1.9 pts | +1.53M sh | +1941% |
| Exited | CRINETICS PHARMACEUTICALS IN (CRNX) | 1.7% | — | −1.7 pts | −128K sh | −100% |
| New | SAREPTA THERAPEUTICS INC (SRPT) | — | 1.6% | +1.6 pts | +42,000 sh | new |
| Increased | CORBUS PHARMACEUTICALS HLDGS (CRBP) | 0.4% | 1.9% | +1.6 pts | +141K sh | +439% |
| Increased | AKERO THERAPEUTICS INC (AKRO) | 2.8% | 3.6% | +0.8 pts | +225K sh | +56% |
| Reduced | PRAXIS PRECISION MEDICINES I (PRAX) | 3.3% | 0.7% | −2.6 pts | −123K sh | −65% |
| Exited | BOUNDLESS BIO INC (BOLD) | 1.2% | — | −1.2 pts | −313K sh | −100% |
| Increased | ABIVAX SA (ABVX) | 0.3% | 1.5% | +1.2 pts | +381K sh | +508% |
| Reduced | SOLID BIOSCIENCES INC (SLDB) | 4.9% | 0.7% | −4.3 pts | −852K sh | −64% |
| New | DISC MEDICINE INC (IRON) | — | 1.1% | +1.1 pts | +101K sh | new |
| Exited | SCHOLAR ROCK HLDG CORP (SRRK) | 1.0% | — | −1.0 pts | −199K sh | −100% |
| Increased | ADC THERAPEUTICS SA (ADCT) | 0.6% | 1.4% | +0.7 pts | +1.27M sh | +253% |
| Exited | CYTOKINETICS INC (CYTK) | 1.0% | — | −1.0 pts | −50,000 sh | −100% |
| Exited | APOGEE THERAPEUTICS INC (APGE) | 0.9% | — | −0.9 pts | −50,000 sh | −100% |
| New | BIOHAVEN LTD (BHVN) | — | 0.9% | +0.9 pts | +100K sh | new |
| Increased | MERUS N V (MRUS) | 7.2% | 9.1% | +2.0 pts | +57,341 sh | +10% |
| New | LONGBOARD PHARMACEUTICALS IN (LBPH) | — | 0.8% | +0.8 pts | +123K sh | new |
| Exited | XENON PHARMACEUTICALS INC (XENE) | 0.8% | — | −0.8 pts | −66,090 sh | −100% |
| Increased | GERON CORP (GERN) | 0.2% | 1.0% | +0.8 pts | +749K sh | +300% |
| Exited | DEXCOM INC (DXCM) | 0.8% | — | −0.8 pts | −20,000 sh | −100% |
| Exited | PLIANT THERAPEUTICS INC (PLRX) | 0.8% | — | −0.8 pts | −183K sh | −100% |
| Exited | ROCKET PHARMACEUTICALS INC (RCKT) | 0.8% | — | −0.8 pts | −101K sh | −100% |
| Increased | CELLDEX THERAPEUTICS INC NEW (CLDX) | 3.5% | 3.4% | −0.1 pts | +75,594 sh | +25% |
| New | BIODESIX INC (BDSXXXXX) | — | 0.7% | +0.7 pts | +1.81M sh | new |
| Exited | NEWAMSTERDAM PHARMA COMPANY (NAMS) | 0.7% | — | −0.7 pts | −99,612 sh | −100% |
| New | ENGENE HOLDINGS INC (ENGN) | — | 0.6% | +0.6 pts | +264K sh | new |
| Increased | VERONA PHARMA PLC (VRNA) | 0.6% | 1.1% | +0.5 pts | +168K sh | +123% |
| Increased | STRUCTURE THERAPEUTICS INC (GPCR) | 0.1% | 0.7% | +0.6 pts | +60,516 sh | +605% |
| Exited | KRYSTAL BIOTECH INC (KRYS) | 0.5% | — | −0.5 pts | −10,000 sh | −100% |
| New | STOKE THERAPEUTICS INC (STOK) | — | 0.5% | +0.5 pts | +142K sh | new |
| Exited | TERNS PHARMACEUTICALS INC (TERN) | 0.5% | — | −0.5 pts | −251K sh | −100% |
| Exited | VIKING THERAPEUTICS INC (VKTX) | 0.5% | — | −0.5 pts | −20,000 sh | −100% |
| Increased | INSMED INC (INSM) | 0.9% | 2.3% | +1.5 pts | +26,384 sh | +23% |
| Exited | AMYLYX PHARMACEUTICALS INC (AMLX) | 0.4% | — | −0.4 pts | −500K sh | −100% |
| Increased | COGENT BIOSCIENCES INC (COGT) | 2.0% | 2.5% | +0.6 pts | +170K sh | +16% |
| Reduced | EYEPOINT PHARMACEUTICALS INC (EYPT) | 1.4% | 0.2% | −1.2 pts | −148K sh | −60% |
| Increased | AVIDITY BIOSCIENCES INC (RNA) | 3.5% | 5.2% | +1.7 pts | +28,431 sh | +6% |
| New | TARSUS PHARMACEUTICALS INC (TARS) | — | 0.3% | +0.3 pts | +40,000 sh | new |
| Increased | TELA BIO INC (TELA) | 1.2% | 1.2% | −0.1 pts | +223K sh | +29% |
| Reduced | MERSANA THERAPEUTICS INC (MRSN) | 3.7% | 1.2% | −2.5 pts | −468K sh | −16% |
| Exited | ADICET BIO INC (ACET) | 0.2% | — | −0.2 pts | −331K sh | −100% |
| Increased | COMPUGEN LTD (CGEN) | 0.7% | 0.6% | −0.1 pts | +501K sh | +50% |
| Exited | MINERALYS THERAPEUTICS INC (MLYS) | 0.2% | — | −0.2 pts | −56,944 sh | −100% |
The 50 largest of 68 changes, by size of the trade. Full holdings for this quarter.
Reported by the fund in its Form 13F filed with the SEC; holdings are as of the quarter-end report date and may have changed since. For informational purposes only — not investment advice or a recommendation to buy or sell any security. FilingExplorer is not affiliated with or endorsed by this fund. How this brief is compiled
† Security identifier (CUSIP) changed — read as one continuing position, not an exit and a new position:
- PERSPECTIVE THERAPEUTICS INC (CATX): 46489V104 → 46489V302, 8.11M → 260K shares (share count changed with the identifier; not shown as a trade)
Top 10 positions — 49.2% of the equity book
Changes in the top 10 this quarter: URGN entered · ERAS entered · AKRO entered · ITCI entered · PSTX entered · SLDB left · ORIC left · MRSN left · CCCC left · PRAX left
| # | Security | Weight before | Weight now | |
|---|---|---|---|---|
| 1 | MERUS N V (MRUS) | 7.2% | 9.1% | |
| 2 | NUVALENT INC (NUVL) | 3.3% | 8.7% | |
| 3 | AVIDITY BIOSCIENCES INC (RNA) | 3.5% | 5.2% | |
| 4 | UROGEN PHARMA LTD (URGN) | 2.1% | 4.6% | Entered the top 10 |
| 5 | ERASCA INC (ERAS) | 0.1% | 4.6% | Entered the top 10 |
| 6 | MORPHIC HLDG INC (MORF) | 4.8% | 4.1% | |
| 7 | AKERO THERAPEUTICS INC (AKRO) | 2.8% | 3.6% | Entered the top 10 |
| 8 | CELLDEX THERAPEUTICS INC NEW (CLDX) | 3.5% | 3.4% | |
| 9 | INTRA-CELLULAR THERAPIES INC (ITCI) | 0.7% | 3.3% | Entered the top 10 |
| 10 | POSEIDA THERAPEUTICS INC (PSTX) | 3.2% | 2.6% | Entered the top 10 |
| — | SOLID BIOSCIENCES INC (SLDB) | 4.9% | 0.7% | Left the top 10 |
| — | ORIC PHARMACEUTICALS INC (ORIC) | 4.3% | 1.9% | Left the top 10 |
| — | MERSANA THERAPEUTICS INC (MRSN) | 3.7% | 1.2% | Left the top 10 |
| — | C4 THERAPEUTICS INC (CCCC) | 3.3% | 1.6% | Left the top 10 |
| — | PRAXIS PRECISION MEDICINES I (PRAX) | 3.3% | 0.7% | Left the top 10 |
Weights are each position's reported value as a share of the fund's reported equity positions (options and principal-amount holdings excluded).
Option positions (puts and calls)
Reported separately from the positions above. The value a 13F reports for an option is that of the underlying shares, not the option itself.
| Activity | Security | Type | Shares before | Shares now | Reported value |
|---|---|---|---|---|---|
| New | INSMED INC (INSM) | Call | 0 | 250K | $16.8M |
| Exited | MACROGENICS INC (MGNX) | Call | 146K | 0 | $0 |
| New | ALX ONCOLOGY HLDGS INC (ALXO) | Put | 0 | 168K | $1.01M |
| Increased | MERSANA THERAPEUTICS INC (MRSN) | Call | 1,700 | 168K | $338K |
| Exited | AMYLYX PHARMACEUTICALS INC (AMLX) | Call | 20,000 | 0 | $0 |